Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts

Wells A. Messersmith, N. V. Rajeshkumar, Aik-Choon Tan, Fei Wang Xiao, Veronica Diesl, Sung E. Choe, Max Follettie, Christina Coughlin, Frank Boschelli, Elena Garcia-Garcia, Fernando Lopez-Rios, Antonio Jimeno, Manuel Hidalgo

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Recently, Src tyrosine kinase has emerged as an attractive target for anticancer therapy, and Src is overexpressed in pancreatic cancer. The purpose of the study was to investigate the in vivo efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, using a panel of human pancreatic tumor xenografts. Surgically resected human pancreatic tumors were implanted into female nude mice and randomized to bosutinib versus control. Src and other pathways were analyzed by Western Blot, IHC, and Affymetrix U133 Plus 2.0 gene arrays. Of 15 patient tumors, 3 patient tumors were found to be sensitive to bosutinib, defined as tumor growth of <45% than that of control tumors. There were no definite differences between sensitive and resistant tumors in the baseline Src kinase pathway protein expression assessed by Western Blot. Caveolin-1 expression, as assessed by reverse transcription-PCR and immunohistochemistry, was frequently higher in sensitive cases. In sensitive tumors, bosutinib resulted in increased apoptosis. Phosphorylation of key signaling molecules downstream of Src, signal transducers and activators of transcription 3, and signal transducers and activators of transcription 3, were significantly inhibited by bosutinib. K-Top Scoring Pairs analysis of gene arrays gave a six-gene classifier that predicted resistance versus sensitivity in six validation cases. These results may aid the clinical development of bosutinib and other Src inhibitors in pancreas cancer.

Original languageEnglish
Pages (from-to)1484-1493
Number of pages10
JournalMolecular Cancer Therapeutics
Volume8
Issue number6
DOIs
Publication statusPublished - 2009 Jun 1
Externally publishedYes

Fingerprint

Pancreatic Neoplasms
Heterografts
Neoplasms
STAT3 Transcription Factor
src-Family Kinases
Western Blotting
Genes
Caveolin 1
bosutinib
Nude Mice
Reverse Transcription
Immunohistochemistry
Phosphorylation
Apoptosis
Polymerase Chain Reaction
Growth
Proteins

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts. / Messersmith, Wells A.; Rajeshkumar, N. V.; Tan, Aik-Choon; Xiao, Fei Wang; Diesl, Veronica; Choe, Sung E.; Follettie, Max; Coughlin, Christina; Boschelli, Frank; Garcia-Garcia, Elena; Lopez-Rios, Fernando; Jimeno, Antonio; Hidalgo, Manuel.

In: Molecular Cancer Therapeutics, Vol. 8, No. 6, 01.06.2009, p. 1484-1493.

Research output: Contribution to journalArticle

Messersmith, WA, Rajeshkumar, NV, Tan, A-C, Xiao, FW, Diesl, V, Choe, SE, Follettie, M, Coughlin, C, Boschelli, F, Garcia-Garcia, E, Lopez-Rios, F, Jimeno, A & Hidalgo, M 2009, 'Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts', Molecular Cancer Therapeutics, vol. 8, no. 6, pp. 1484-1493. https://doi.org/10.1158/1535-7163.MCT-09-0075
Messersmith, Wells A. ; Rajeshkumar, N. V. ; Tan, Aik-Choon ; Xiao, Fei Wang ; Diesl, Veronica ; Choe, Sung E. ; Follettie, Max ; Coughlin, Christina ; Boschelli, Frank ; Garcia-Garcia, Elena ; Lopez-Rios, Fernando ; Jimeno, Antonio ; Hidalgo, Manuel. / Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts. In: Molecular Cancer Therapeutics. 2009 ; Vol. 8, No. 6. pp. 1484-1493.
@article{1fce2a946c5a47d9aa033f0cc5a41f5a,
title = "Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts",
abstract = "Recently, Src tyrosine kinase has emerged as an attractive target for anticancer therapy, and Src is overexpressed in pancreatic cancer. The purpose of the study was to investigate the in vivo efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, using a panel of human pancreatic tumor xenografts. Surgically resected human pancreatic tumors were implanted into female nude mice and randomized to bosutinib versus control. Src and other pathways were analyzed by Western Blot, IHC, and Affymetrix U133 Plus 2.0 gene arrays. Of 15 patient tumors, 3 patient tumors were found to be sensitive to bosutinib, defined as tumor growth of <45{\%} than that of control tumors. There were no definite differences between sensitive and resistant tumors in the baseline Src kinase pathway protein expression assessed by Western Blot. Caveolin-1 expression, as assessed by reverse transcription-PCR and immunohistochemistry, was frequently higher in sensitive cases. In sensitive tumors, bosutinib resulted in increased apoptosis. Phosphorylation of key signaling molecules downstream of Src, signal transducers and activators of transcription 3, and signal transducers and activators of transcription 3, were significantly inhibited by bosutinib. K-Top Scoring Pairs analysis of gene arrays gave a six-gene classifier that predicted resistance versus sensitivity in six validation cases. These results may aid the clinical development of bosutinib and other Src inhibitors in pancreas cancer.",
author = "Messersmith, {Wells A.} and Rajeshkumar, {N. V.} and Aik-Choon Tan and Xiao, {Fei Wang} and Veronica Diesl and Choe, {Sung E.} and Max Follettie and Christina Coughlin and Frank Boschelli and Elena Garcia-Garcia and Fernando Lopez-Rios and Antonio Jimeno and Manuel Hidalgo",
year = "2009",
month = "6",
day = "1",
doi = "10.1158/1535-7163.MCT-09-0075",
language = "English",
volume = "8",
pages = "1484--1493",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts

AU - Messersmith, Wells A.

AU - Rajeshkumar, N. V.

AU - Tan, Aik-Choon

AU - Xiao, Fei Wang

AU - Diesl, Veronica

AU - Choe, Sung E.

AU - Follettie, Max

AU - Coughlin, Christina

AU - Boschelli, Frank

AU - Garcia-Garcia, Elena

AU - Lopez-Rios, Fernando

AU - Jimeno, Antonio

AU - Hidalgo, Manuel

PY - 2009/6/1

Y1 - 2009/6/1

N2 - Recently, Src tyrosine kinase has emerged as an attractive target for anticancer therapy, and Src is overexpressed in pancreatic cancer. The purpose of the study was to investigate the in vivo efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, using a panel of human pancreatic tumor xenografts. Surgically resected human pancreatic tumors were implanted into female nude mice and randomized to bosutinib versus control. Src and other pathways were analyzed by Western Blot, IHC, and Affymetrix U133 Plus 2.0 gene arrays. Of 15 patient tumors, 3 patient tumors were found to be sensitive to bosutinib, defined as tumor growth of <45% than that of control tumors. There were no definite differences between sensitive and resistant tumors in the baseline Src kinase pathway protein expression assessed by Western Blot. Caveolin-1 expression, as assessed by reverse transcription-PCR and immunohistochemistry, was frequently higher in sensitive cases. In sensitive tumors, bosutinib resulted in increased apoptosis. Phosphorylation of key signaling molecules downstream of Src, signal transducers and activators of transcription 3, and signal transducers and activators of transcription 3, were significantly inhibited by bosutinib. K-Top Scoring Pairs analysis of gene arrays gave a six-gene classifier that predicted resistance versus sensitivity in six validation cases. These results may aid the clinical development of bosutinib and other Src inhibitors in pancreas cancer.

AB - Recently, Src tyrosine kinase has emerged as an attractive target for anticancer therapy, and Src is overexpressed in pancreatic cancer. The purpose of the study was to investigate the in vivo efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, using a panel of human pancreatic tumor xenografts. Surgically resected human pancreatic tumors were implanted into female nude mice and randomized to bosutinib versus control. Src and other pathways were analyzed by Western Blot, IHC, and Affymetrix U133 Plus 2.0 gene arrays. Of 15 patient tumors, 3 patient tumors were found to be sensitive to bosutinib, defined as tumor growth of <45% than that of control tumors. There were no definite differences between sensitive and resistant tumors in the baseline Src kinase pathway protein expression assessed by Western Blot. Caveolin-1 expression, as assessed by reverse transcription-PCR and immunohistochemistry, was frequently higher in sensitive cases. In sensitive tumors, bosutinib resulted in increased apoptosis. Phosphorylation of key signaling molecules downstream of Src, signal transducers and activators of transcription 3, and signal transducers and activators of transcription 3, were significantly inhibited by bosutinib. K-Top Scoring Pairs analysis of gene arrays gave a six-gene classifier that predicted resistance versus sensitivity in six validation cases. These results may aid the clinical development of bosutinib and other Src inhibitors in pancreas cancer.

UR - http://www.scopus.com/inward/record.url?scp=67649366381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649366381&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-09-0075

DO - 10.1158/1535-7163.MCT-09-0075

M3 - Article

C2 - 19509264

AN - SCOPUS:67649366381

VL - 8

SP - 1484

EP - 1493

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 6

ER -